Fate Therapeutics, Inc. (FATE)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 11:44AM EDT. Market open.
| Previous close | 5.55 |
| Open | 5.61 |
| Bid | 5.42 x 800 |
| Ask | 5.43 x 1400 |
| Day's range | 5.41 - 5.66 |
| 52-week range | 4.02 - 43.12 |
| Volume | |
| Avg. volume | 3,904,213 |
| Market cap | 526.664M |
| Beta (5Y monthly) | 1.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.80 |
| Earnings date | 02 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.27 |
- Zacks
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
- GlobeNewswire
Fate Therapeutics to Present at Upcoming March Investor Conferences
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: 43rd Annual TD Cowen Health Care Conference on Wednesday, March
- Simply Wall St.
Fate Therapeutics Full Year 2022 Earnings: Beats Expectations
Fate Therapeutics ( NASDAQ:FATE ) Full Year 2022 Results Key Financial Results Revenue: US$96.3m (up 72% from FY 2021...
© 2023 Yahoo. All rights reserved.
